The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Pieris Pharmaceuticals shares have lost about 1.2% since the beginning of the year versus the S&P 500's gain of 5.7%. What's Next for Pieris Pharmaceuticals? While Pieris Pharmaceuticals has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?